Orion Corporation stock analysis
Orion Corporation (0M2O) Share Price & Analysis
0M2O Stock Chart & Stats
- Day’s Range
- EUR 102.40 - EUR 103.80
- 52-Week Range
- EUR 58.80 - EUR 103.80
- Previous Close
- EUR 103.00
- Volume
- N/A
- Average Volume (3M)
- 57.07K
- Market Cap
- EUR 14.47B
- Enterprise Value
- EUR 11.69B
- Total Cash (Recent Filing)
- EUR 259.40M
- Total Debt (Recent Filing)
- EUR 0
- Price to Earnings (P/E)
- 22.0
- Beta
- 1.06
- Next Earnings
- Feb 17, 2027 (Est.)
- EPS Estimate
- 1.47
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 1.74%
Orion Corporation News
0M2O FAQ
What was Orion Corporation’s price range in the past 12 months?
What is Orion Corporation’s market cap?
When is Orion Corporation’s upcoming earnings report date?
How were Orion Corporation’s earnings last quarter?
Is Orion Corporation overvalued?
Does Orion Corporation pay dividends?
What is Orion Corporation’s EPS estimate?
How many shares outstanding does Orion Corporation have?
What happened to Orion Corporation’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Orion Corporation?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Orion Corporation
Orion Oyj is a global pharmaceutical company engaged in the research, development, manufacturing, and commercialization of human and veterinary medicines, alongside active pharmaceutical ingredients (APIs). Its market reach extends across Finland, the Nordic countries, wider Europe, North America, and other international territories. The company's human health division offers both prescription drugs and self-care products. Its key prescription medications include Nubeqa for prostate cancer treatment, dexdor and Precedex for intensive care sedation, and therapies like Stalevo and Comtess/Comtan for Parkinson's disease. Other significant human products are Simdax for acute decompensated heart failure and Fareston for breast cancer. Orion also provides a comprehensive suite of Easyhaler-branded drugs, such as Salmeterol/fluticasone, Budesonide/formoterol, Formoterol, Budesonide, Beclomet, and Buventol, all designed to treat asthma and chronic obstructive pulmonary disease (COPD). In the animal health sector, Orion offers veterinary pharmaceuticals including Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie. Beyond its own product line, the company manufactures APIs for both generic and proprietary drugs and provides contract manufacturing services. Orion also acts as a distributor, marketing and selling veterinary medicines produced by other international companies. Its customer base is broad, serving various healthcare providers and professionals, including specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories, as well as direct consumers with pets. Orion Oyj fosters strategic partnerships, notably with Propeller Health to embed connectivity into its Easyhaler® portfolio for asthma and COPD, and a research collaboration and license agreement with Alligator Bioscience AB (publ) focusing on the discovery and advancement of innovative bispecific antibody cancer therapeutics. Founded in 1917, Orion Oyj is headquartered in Espoo, Finland.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Aino Anna Liisa Hurme
- Employees
- 4,215
- Website
- www.orionpharma.com
- Address
- Orionintie 1A, Espoo, UU, 02200, FI
Orion Corporation (0M2O) Earnings & Revenues
0M2O Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 3 | 4 |
| Technical Analysis | 3 | 3 | 4 |
| Moving Averages | 12 | 0 | 0 |
Similar Stocks
| Company | Price & Change | Follow |
|---|---|---|
| GB:GUNGunsynd |









